JPH0641135A - Imidazopteridine derivative and its production - Google Patents
Imidazopteridine derivative and its productionInfo
- Publication number
- JPH0641135A JPH0641135A JP4214794A JP21479492A JPH0641135A JP H0641135 A JPH0641135 A JP H0641135A JP 4214794 A JP4214794 A JP 4214794A JP 21479492 A JP21479492 A JP 21479492A JP H0641135 A JPH0641135 A JP H0641135A
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- group
- formula
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は新規なイミダゾプテリジ
ン誘導体及びその製造方法に関する。TECHNICAL FIELD The present invention relates to a novel imidazopteridine derivative and a method for producing the same.
【0002】[0002]
【従来の技術】イミダゾプテリジン誘導体は古くから知
られており数多くの報告例がある。しかし、そのらの多
くは構造異性体であるイミダゾ〔1,2,3−ij〕プ
テリジン誘導体、イミダゾ〔1,6−f〕プテリジン誘
導体やイミダゾ〔5,4−g〕プテリジン誘導体に関す
るものであり、本発明化合物と同じ骨格を有するイミダ
ゾ〔4,5−g〕プテリジンタイプにおいてはわずかに
知られているにすぎない。それらは例えば、プテリジン
誘導体からの合成により得られる化合物〔(化5)、
(化6)〕〔J.Am.Chem.Soc.,81,2
464−71(1959)、J.Am.Chem.So
c.,85,1203−6(1963)〕やイミダゾリ
ン誘導体とウラシル誘導体との縮合もしくはピリミジン
誘導体との縮合により得られる化合物〔(化7)、(化
8)〕〔Heterocycles,1978,10,
45−51)及びエチル基が二置換した化合物〔(化
9)〕〔Monatsh.Chem.,1986,11
7(6−7),879−82〕等である。2. Description of the Related Art Imidazopteridine derivatives have been known for a long time and there are many reports. However, most of them are related to structural isomers such as imidazo [1,2,3-ij] pteridine derivatives, imidazo [1,6-f] pteridine derivatives and imidazo [5,4-g] pteridine derivatives. However, it is only slightly known in the imidazo [4,5-g] pteridine type having the same skeleton as the compound of the present invention. They are, for example, compounds obtained by synthesis from pteridine derivatives [(Chemical formula 5),
(Chemical formula 6)] [J. Am. Chem. Soc. , 81, 2
464-71 (1959), J. Am. Chem. So
c. , 85, 1203-6 (1963)] or a compound obtained by condensation of an imidazoline derivative and a uracil derivative or a pyrimidine derivative [(Chemical formula 7), (Chemical formula 8)] [Heterocycles, 1978, 10,
45-51) and a compound disubstituted with an ethyl group [(chemical formula 9)] [Monatsh. Chem. , 1986, 11
7 (6-7), 879-82] and the like.
【0003】[0003]
【化5】 [Chemical 5]
【0004】[0004]
【化6】 [Chemical 6]
【0005】[0005]
【化7】 [Chemical 7]
【0006】[0006]
【化8】 [Chemical 8]
【0007】[0007]
【化9】 [Chemical 9]
【0008】[0008]
【本発明が解決しようとする課題】本発明の目的は、簡
単に合成できる新規イミダゾプテリジン誘導体を提供す
ることにある。An object of the present invention is to provide a novel imidazopteridine derivative which can be easily synthesized.
【0009】[0009]
【課題を解決するための手段】本発明者等は3,6−ジ
アミノ−2,5−ピラジンジカルボニトリル〔II〕(特
願平2−59935号)及びピリミド〔4,5−g〕プ
テリジン誘導体〔IV〕(特願平4−31356)を先に
見い出している。これら化合物〔II〕、〔IV〕を出発原
料として鋭意検討した結果、容易に本発明化合物を合成
できることを見い出した。The present inventors have found that 3,6-diamino-2,5-pyrazinedicarbonitrile [II] (Japanese Patent Application No. 2-59935) and pyrimido [4,5-g] pteridine. The derivative [IV] (Japanese Patent Application No. 4-31356) has been found first. As a result of extensive studies using these compounds [II] and [IV] as starting materials, it was found that the compound of the present invention can be easily synthesized.
【0010】即ち、本発明は一般式〔I〕That is, the present invention has the general formula [I]
【化10】 〔式中、R1 とR2 は同一又は相異なって置換基を有し
てもよいアルキル基、置換基を有してもよいアルケニル
基、置換基を有してもよいアルキニル基、置換基を有し
てもよいシクロアルキル基、置換基を有してもよいアリ
ール基または置換基を有してもよいヘテロ環基、R3 は
水素原子、置換基を有してもよいアルキル基、置換基を
有してもよいアルケニル基、置換基を有してもよいアル
キニル基、置換基を有してもよいシクロアルキル基、R
4 は水素原子、置換基を有してもよいアルキル基、置換
基を有してもよいアルケニル基、置換基を有してもよい
アルキニル基、置換基を有してもよいシクロアルキル
基、又はCONHR5 (R5は置換基を有してもよいア
ルキル基、置換基を有してもよいアルケニル基、置換基
を有してもよいアルキニル基、置換基を有してもよいシ
クロアルキル基、置換基を有してもよいアリール基また
は置換基を有してもよいヘテロ環基を示す。)、XはN
Hまたは酸素原子を示す(但し、R1 、R2 、R3 及び
R4 が全てメチル基でXが酸素原子の場合とR1 とR3
が水素原子、R2 とR4 がエチル基でXが酸素原子の場
合を除く。)。〕で表される化合物及びその製造方法で
ある。[Chemical 10] [In the formula, R 1 and R 2 are the same or different and each may have a substituent, an alkyl group which may have a substituent, an alkynyl group which may have a substituent, a substituent A cycloalkyl group which may have a substituent, an aryl group which may have a substituent or a heterocyclic group which may have a substituent, R 3 represents a hydrogen atom, an alkyl group which may have a substituent, An alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a cycloalkyl group which may have a substituent, R
4 is a hydrogen atom, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a cycloalkyl group which may have a substituent, Or CONHR 5 (R 5 is an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a cycloalkyl which may have a substituent) Group, an aryl group which may have a substituent or a heterocyclic group which may have a substituent), and X is N.
H or an oxygen atom (provided that R 1 , R 2 , R 3 and R 4 are all methyl groups and X is an oxygen atom, R 1 and R 3
Is a hydrogen atom, R 2 and R 4 are ethyl groups, and X is an oxygen atom. ). ] It is a compound represented by these, and its manufacturing method.
【0011】R1 、R2 、R3 、R4 、R5 においてア
ルキル基、アルケニル基、アルキニル基、シクロアルキ
ル基が置換基を有する場合、その置換基としては、例え
ば置換基を有してもよいフェニル基等のアリール基、シ
アノ基、ニトロ基、アルコキシ基、アリールオキシ基、
アルキルチオ基、アリールチオ基、ハロゲン原子等が挙
げられる。R1 、R2 、R5 においてアリール基、ヘテ
ロ環基が置換基を有する場合、その置換基としては、例
えばアルキル基、アルケニル基、アルキニル基、アルコ
キシ基、アリールオキシ基、ニトロ基、シアノ基、アル
キルチオ基、アリールチオ基、アルコキシカルボニル
基、ハロゲン原子等か挙げられ、これらの基の中で可能
なものは更に置換基を有してもよい。置換基の個数及び
その結合位置は任意であり、複数の置換基が結合してい
る場合、それらは互いに同じでも異なっていてもよい。When the alkyl group, alkenyl group, alkynyl group or cycloalkyl group in R 1 , R 2 , R 3 , R 4 and R 5 has a substituent, the substituent may be, for example, a substituent. Aryl group such as phenyl group, cyano group, nitro group, alkoxy group, aryloxy group,
Examples thereof include an alkylthio group, an arylthio group and a halogen atom. When the aryl group or heterocyclic group in R 1 , R 2 or R 5 has a substituent, examples of the substituent include an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, a nitro group and a cyano group. , An alkylthio group, an arylthio group, an alkoxycarbonyl group, a halogen atom and the like, and those possible among these groups may further have a substituent. The number of substituents and the bonding position thereof are arbitrary, and when a plurality of substituents are bonded, they may be the same or different from each other.
【0012】本発明化合物の製造方法を説明する。 (1)The method for producing the compound of the present invention will be described. (1)
【化11】 r1 は前記と同じ意味を示す。化合物〔II〕に対し適当
なイソシアナート化合物を3倍モル以上用い、適当な溶
媒中で−50℃から180℃、好ましくは−20℃から
150℃で、3倍以上の塩基を添加し反応させることに
より得ることができる。溶媒としては、ジメチルホルム
アミド(DMF)、ジメチルアセトアミド(DMA
C)、ジメチルスルホキシド(DMSO)、テトラヒド
ロフラン(THF)やジメトキシエタン(DME)など
の極性溶媒などが挙げられ、単独又は混合溶媒で使用さ
れる。塩基としては炭酸ナトリウムや炭酸カリウムなど
の炭酸塩、水酸化ナトリウムや水酸化カリウムなどの水
酸化物、ナトリウムメトキシドやカリウムt−ブトキシ
ドなどのアルコキシド類、水素化ナトリウムや水素化カ
リウム等の金属水素化物などが使用できる。[Chemical 11] r 1 has the same meaning as described above. A suitable isocyanate compound is used in an amount of 3 times by mole or more with respect to the compound [II], and the reaction is carried out in an appropriate solvent at −50 ° C. to 180 ° C., preferably −20 ° C. to 150 ° C., by adding 3 times or more base. Can be obtained. As the solvent, dimethylformamide (DMF), dimethylacetamide (DMA)
C), dimethylsulfoxide (DMSO), polar solvents such as tetrahydrofuran (THF) and dimethoxyethane (DME), and the like, and they are used alone or in a mixed solvent. As the base, carbonates such as sodium carbonate and potassium carbonate, hydroxides such as sodium hydroxide and potassium hydroxide, alkoxides such as sodium methoxide and potassium t-butoxide, metal hydrogen such as sodium hydride and potassium hydride. Compounds can be used.
【0013】(2)(2)
【化12】 R1 、R2 、R3 及びR4 は前記と同じ意味を示す。一
般式〔IV〕で表される化合物を適当な溶媒中で−50℃
から180℃好ましくは−20℃から150℃下で触媒
量から等量以上の塩基を添加し反応させることによって
得ることができる。溶媒および塩基は(1)に挙げたも
のが用いられる。反応終了後は通常の後処理を行うこと
により、目的物を得ることができる。合成した化合物は
NMR、IR、MASS等により同定した。[Chemical 12] R 1 , R 2 , R 3 and R 4 have the same meanings as described above. The compound represented by the general formula [IV] is stored in a suitable solvent at -50 ° C.
To 180 ° C., preferably −20 ° C. to 150 ° C., and can be obtained by adding and reacting a base in a catalytic amount to an equivalent amount or more. As the solvent and the base, those listed in (1) are used. After completion of the reaction, the target product can be obtained by performing a usual post-treatment. The synthesized compound was identified by NMR, IR, MASS and the like.
【0014】[0014]
【実施例】本発明を実施例によって更に具体的に説明す
るが、本発明の範囲はこれらの実施例によって限定され
るものではない。EXAMPLES The present invention will be described in more detail with reference to examples, but the scope of the present invention is not limited to these examples.
【0015】実施例1(化合物番号1)Example 1 (Compound No. 1)
【化13】 窒素雰囲気下、3,6−ジアミノ−2,5−ピラジンジ
カルボニトリル〔II〕1.60g(10.0mmol)
とn−プロピルイソシアナート3.8ml(40.5m
mol)の無水DMF(15ml)溶液を氷冷し、60
%含有油性水素化ナトリウム1.76g(44.0mm
ol)を加えた。1.5時間後氷水100mlにあけ希
塩酸で酸性にした後結晶を濾取し、酢酸エチル、次いで
水で洗浄した。得られた赤橙色結晶をジクロロメタンと
酢酸エチルの混合溶媒(約3対1、350ml)に入れ
よく撹拌し、濾過した。濾液を減圧濃縮し黄色結晶0.
75g(1.9mmol)を得た。更に再結晶(酢酸エ
チル)を行い淡黄色結晶を得た。 収率19%、244℃(吸熱ピーク)* * 吸熱ピークあるいは発熱ピークの記載のある項は、D
SCによる測定値である。(以下、実施例、表において
も同じ)[Chemical 13] Under nitrogen atmosphere, 3,6-diamino-2,5-pyrazinedicarbonitrile [II] 1.60 g (10.0 mmol)
And n-propyl isocyanate 3.8 ml (40.5 m
(mol) anhydrous DMF (15 ml) solution was ice-cooled to 60
% Oily sodium hydride 1.76 g (44.0 mm)
ol) was added. After 1.5 hours, the mixture was poured into 100 ml of ice water and acidified with dilute hydrochloric acid, and the crystals were collected by filtration and washed with ethyl acetate and then with water. The obtained reddish orange crystals were put into a mixed solvent of dichloromethane and ethyl acetate (about 3: 1 and 350 ml), well stirred, and filtered. The filtrate was concentrated under reduced pressure to give yellow crystals.
75 g (1.9 mmol) was obtained. Further, recrystallization (ethyl acetate) was performed to obtain pale yellow crystals. Yield 19%, 244 ° C (endothermic peak) * * Items with an endothermic peak or exothermic peak are D
It is the value measured by SC. (The same applies to the following examples and tables)
【0016】実施例2(化合物番号3)Example 2 (Compound No. 3)
【化14】 窒素雰囲気下、3,6−ジアミノ−2,5−ピラジンジ
カルボニトリル〔II〕0.48g(3.0mmol)と
n−ブチルイソシアナート1.0ml(8.9mmo
l)の無水DMAC(15ml)溶液を氷冷し、60%
含有油性水素化ナトリウム0.60g(15.0mmo
l)を加えた。10分後室温まで昇温し、2時間後更に
n−ブチルイソシアナート1.0ml(8.9mmo
l)と水素化ナトリウム0.60g(15.0mmo
l)を加え、10時間撹拌した。氷水100mlにあけ
濃塩酸で酸性にした後、酢酸エチルで抽出した。有機層
を合わせ水洗し、無水硫酸マグネシウムで乾燥した。減
圧濃縮後、シリカゲルカラムクロマトグラフィー(展開
溶媒;ベンゼン−酢酸エチル 1対1)で精製を行な
い、黄色結晶の目的物を0.58g(1.3mmol)
を得た。更に再結晶(ジクロロメタン−n−ヘキサン)
を行ない黄色結晶を得た。収率43%、212℃(吸熱
ピーク)[Chemical 14] Under a nitrogen atmosphere, 0.48 g (3.0 mmol) of 3,6-diamino-2,5-pyrazinedicarbonitrile [II] and 1.0 ml of n-butyl isocyanate (8.9 mmo).
A solution of 1) in anhydrous DMAC (15 ml) was ice-cooled to 60%.
Containing oily sodium hydride 0.60g (15.0mmo
l) was added. After 10 minutes, the temperature was raised to room temperature, and after 2 hours, 1.0 ml of n-butyl isocyanate (8.9 mmo).
l) and sodium hydride (0.60 g, 15.0 mmo)
1) was added and stirred for 10 hours. The mixture was poured into 100 ml of ice water, acidified with concentrated hydrochloric acid, and extracted with ethyl acetate. The organic layers were combined, washed with water, and dried over anhydrous magnesium sulfate. After concentration under reduced pressure, purification was performed by silica gel column chromatography (developing solvent; benzene-ethyl acetate 1: 1) to obtain 0.58 g (1.3 mmol) of the desired product as yellow crystals.
Got Further recrystallization (dichloromethane-n-hexane)
And yellow crystals were obtained. Yield 43%, 212 ° C (endothermic peak)
【0017】実施例3(化合物番号6)Example 3 (Compound No. 6)
【化15】 化合物〔IV〕においてr1 、R3 及びr4 が全てn−ブ
チル基である化合物0.24g(0.51mmol)の
DMAC(5ml)溶液に炭酸カリウム69mg(0.
5mmol)を加え、約100℃で20時間反応を行な
い、更に炭酸カリウム69mg(0.5mmol)を加
え、約150℃で6時間反応を行なった。放冷後、水8
0mlを加え希塩酸で弱酸性とし、ジクロロメタンで抽
出した。有機層を合わせ水洗し、無水硫酸マグネシウム
で乾燥した。減圧濃縮し、シリカゲルカラムクロマトグ
ラフィー(展開溶媒;ベンゼン−酢酸エチル 10対
1)で精製を行ない、淡黄色結晶の目的物を0.12g
(0.27mmol)得た。 収率53%、mp83−84℃[Chemical 15] In a DMAC (5 ml) solution of a compound [IV] in which r 1 , R 3 and r 4 are all n-butyl groups in a DMAC (5 ml) solution, 69 mg (0.
5 mmol) was added and the reaction was carried out at about 100 ° C. for 20 hours, 69 mg (0.5 mmol) of potassium carbonate was further added, and the reaction was carried out at about 150 ° C. for 6 hours. After cooling down, water 8
0 ml was added to weakly acidify with dilute hydrochloric acid, and the mixture was extracted with dichloromethane. The organic layers were combined, washed with water, and dried over anhydrous magnesium sulfate. Concentrate under reduced pressure and purify by silica gel column chromatography (developing solvent; benzene-ethyl acetate 10: 1) to obtain 0.12 g of the desired product as pale yellow crystals.
(0.27 mmol) was obtained. Yield 53%, mp 83-84 ° C
【0018】上記実施例を含め、本発明化合物の代表例
を表−1に示す。又、表−2にそれらの蛍光特性を示
す。Representative examples of the compounds of the present invention, including the above examples, are shown in Table 1. In addition, Table 2 shows their fluorescent properties.
【0019】[0019]
【表1】 [Table 1]
【0020】[0020]
【表2】 [Table 2]
【0021】[0021]
【発明の効果】本発明化合物は、農医薬、顔料・染料等
の中間原料又は蛍光色素として有用である。INDUSTRIAL APPLICABILITY The compound of the present invention is useful as an intermediate raw material for agricultural medicine, pigments and dyes, or as a fluorescent dye.
Claims (3)
てもよいアルキル基、置換基を有してもよいアルケニル
基、置換基を有してもよいアルキニル基、置換基を有し
てもよいシクロアルキル基、置換基を有してもよいアリ
ール基又は置換基を有してもよいヘテロ環基、R3 は水
素原子、置換基を有してもよいアルキル基、置換基を有
してもよいアルケニル基、置換基を有してもよいアルキ
ニル基、置換基を有してもよいシクロアルキル基、R4
は水素原子、置換基を有してもよいアルキル基、置換基
を有してもよいアルケニル基、置換基を有してもよいア
ルキニル基、置換基を有してもよいシクロアルキル基、
又はCONHR5 (R5 は置換基を有してもよいアルキ
ル基、置換基を有してもよいアルケニル基、置換基を有
してもよいアルキニル基、置換基を有してもよいシクロ
アルキル基、置換基を有してもよいアリール基又は置換
基を有してもよいヘテロ環基を示す。)、XはNHまた
は酸素原子を示す(但し、R1 、R2 、R3 及びR4 が
全てメチル基でXが酸素原子の場合とR1 とR3 が水素
原子、R2 とR4 がエチル基でXが酸素原子の場合を除
く。)。〕で表される化合物。1. A compound represented by the general formula [I]: [In the formula, R 1 and R 2 are the same or different and each may have a substituent, an alkyl group which may have a substituent, an alkynyl group which may have a substituent, a substituent A cycloalkyl group which may have a substituent, an aryl group which may have a substituent or a heterocyclic group which may have a substituent, R 3 represents a hydrogen atom, an alkyl group which may have a substituent, An alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a cycloalkyl group which may have a substituent, R 4
Is a hydrogen atom, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a cycloalkyl group which may have a substituent,
Or CONHR 5 (R 5 is an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a cycloalkyl which may have a substituent) Group, an aryl group which may have a substituent or a heterocyclic group which may have a substituent), X represents NH or an oxygen atom (provided that R 1 , R 2 , R 3 and R Except when all 4 are methyl groups and X is an oxygen atom, and when R 1 and R 3 are hydrogen atoms, R 2 and R 4 are ethyl groups and X is an oxygen atom). ] The compound represented by these.
カルボニトリル〔II〕と一般式〔III〕 r1 NCO 〔III〕 (式中、r1 は置換基を有してもよいアルキル基、置換
基を有してもよいアルケニル基、置換基を有してもよい
アルキニル基、置換基を有してもよいシクロアルキル
基、置換基を有してもよいアリール基または置換基を有
してもよいヘテロ環基を示す。)で表される化合物を塩
基存在下に反応させることを特徴とする一般式〔I−
1〕 【化2】 (式中、r1 は前記と同じ意味を示す。)で表される化
合物の製造方法。2. 3,6-Diamino-2,5-pyrazinedicarbonitrile [II] and general formula [III] r 1 NCO [III] (wherein r 1 is an alkyl which may have a substituent). A group, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a cycloalkyl group which may have a substituent, an aryl group which may have a substituent or a substituent A heterocyclic group which may be present) is reacted in the presence of a base.
1] [Chemical formula 2] (In the formula, r 1 has the same meaning as described above.) A method for producing a compound represented by the formula.
示す。)で表される化合物を塩基存在下に反応させるこ
とを特徴とする一般式〔I−2〕 【化4】 (式中、R1 、R2 、R3 及びR4 は前記と同じ意味を
示す。)で表される化合物の製造方法。3. A compound represented by the general formula [IV]: (In the formula, R 1 , R 2 , R 3 and R 4 have the same meanings as described above.) The compound represented by the general formula [I-2] 4] (Wherein R 1 , R 2 , R 3 and R 4 have the same meanings as described above).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4214794A JPH0641135A (en) | 1992-07-21 | 1992-07-21 | Imidazopteridine derivative and its production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4214794A JPH0641135A (en) | 1992-07-21 | 1992-07-21 | Imidazopteridine derivative and its production |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0641135A true JPH0641135A (en) | 1994-02-15 |
Family
ID=16661643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4214794A Pending JPH0641135A (en) | 1992-07-21 | 1992-07-21 | Imidazopteridine derivative and its production |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0641135A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018866A1 (en) * | 1996-10-25 | 1998-05-07 | Ciba Specialty Chemicals Holding Inc. | Process for colouring high molecular weight organic material and polycyclic pigments |
EP2069352A2 (en) * | 2006-08-02 | 2009-06-17 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
KR20150036509A (en) | 2012-08-21 | 2015-04-07 | 가부시키가이샤 고베 세이코쇼 | Kneading rotor and kneading machine |
US10272082B2 (en) | 2011-07-13 | 2019-04-30 | Cytokinetics, Inc. | Combination ALS therapy |
-
1992
- 1992-07-21 JP JP4214794A patent/JPH0641135A/en active Pending
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018866A1 (en) * | 1996-10-25 | 1998-05-07 | Ciba Specialty Chemicals Holding Inc. | Process for colouring high molecular weight organic material and polycyclic pigments |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
EP2583970A1 (en) * | 2006-08-02 | 2013-04-24 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods comprising imidazopyrimidines |
EP2069352A4 (en) * | 2006-08-02 | 2010-10-27 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
CN102993204A (en) * | 2006-08-02 | 2013-03-27 | 赛特凯恩蒂克公司 | Certain chemical entities, compositions and methods |
EP2069352A2 (en) * | 2006-08-02 | 2009-06-17 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
EP2666777A1 (en) * | 2006-08-02 | 2013-11-27 | Cytokinetics, Inc. | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods |
US8716291B2 (en) | 2006-08-02 | 2014-05-06 | Cytokinetics, Inc. | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
JP2015199737A (en) * | 2006-08-02 | 2015-11-12 | サイトキネティクス・インコーポレーテッドCytokinetics Incorporated | Certain chemical entity, composition and method |
EP2995619A1 (en) * | 2006-08-02 | 2016-03-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods comprising imidazopyrimidines |
US10766899B2 (en) | 2006-08-02 | 2020-09-08 | Cytokinetics, Incorporated | Methods for preparing substituted imidazo[4,5-b]pyrazines |
US10272082B2 (en) | 2011-07-13 | 2019-04-30 | Cytokinetics, Inc. | Combination ALS therapy |
KR20150036509A (en) | 2012-08-21 | 2015-04-07 | 가부시키가이샤 고베 세이코쇼 | Kneading rotor and kneading machine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4631703B2 (en) | Method for producing pyrimidin-4-one compound | |
TW201945343A (en) | Process for the preparation of a diarylthiohydantoin compound | |
HUE029528T2 (en) | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | |
CN111675662A (en) | Preparation method of 2-trifluoromethyl substituted quinazolinone compound | |
JPH0641135A (en) | Imidazopteridine derivative and its production | |
KR20190013554A (en) | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
KR20190103944A (en) | Method for preparing gamma lactam derivatives from nitrocompound using highly enantioselective bifunctional chiral organocatalytic compound | |
JP3047551B2 (en) | Cyanopyrazine derivatives | |
JPH061776A (en) | Production of substituted pyrazinecarbonitrile | |
JPH0641134A (en) | Pyrimidopteridine derivative and its production | |
JPH02289563A (en) | Improved process for producing ortho-carboxypyridyl- and ortho-carboxyquinolylimidazolinones | |
JPH0665213A (en) | Dicyanopyrazine derivative and its production | |
RU2241710C1 (en) | Method for preparing substituted pyrido[1,2-a][1,3]-benzimidazoles | |
JP3338872B2 (en) | Method for producing 1,2-benzisothiazolinone compound | |
CN113200902B (en) | Polysubstituted pyrrole derivative and preparation method thereof | |
KR100497105B1 (en) | 3,4-Dihydroquinazoline Derivatives and Process for the Preparation Thereof | |
CN109988172B (en) | Synthesis method of pyrazolo [1,5-A ] pyrimidine heterocyclic compound and derivative | |
JP5079809B2 (en) | Methods for the synthesis and synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo [1,5-a] pyrimidin-7-yl) -amino derivatives and intermediates Intermediate | |
JPH06228103A (en) | New octahydroacridine derivative and its production | |
KR100382715B1 (en) | Process for the preparation of 4-hydroxythiocoumarin and nitrogen analogues thereof | |
JP2671401B2 (en) | .ALPHA.-Aminothioacetamide derivative and its production method | |
JPH06228149A (en) | Novel pentacyclic heterocyclic compound, production intermediate and their production | |
JP3804208B2 (en) | Method for producing azulene derivatives | |
Nematpour et al. | An Efficient Synthesis of Spiro-Pyrimidines Derivatives Containing a Sulfonyl Scaffold | |
JP3221151B2 (en) | Method for producing pyrrole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |